# TRADEMARK ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | RELEASE BY SECURED PARTY |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|---|---|---|---|
| Credit Suisse AG | FORMERLY Credit Suisse First Boston | 09/22/2010 | CORPORATION: SWITZERLAND |

RECEIVING PARTY DATA

| | |
|---|---|
| Name: | GlaxoSmithKline LLC |
| Street Address: | 2711 Centerville Road, Suite 400 |
| Internal Address: | Corporation Service Company |
| City: | Wilmington |
| State/Country: | DELAWARE |
| Postal Code: | 19801 |
| Entity Type: | CORPORATION: DELAWARE |

PROPERTY NUMBERS Total: 6

| Property Type | Number | Word Mark |
|---|---|---|
| Serial Number: | 75888000 | RELIANT PHARMACEUTICALS |
| Serial Number: | 75516493 | |
| Serial Number: | 74162689 | DYNACIRC CR |
| Serial Number: | 73591689 | DYNACIRC |
| Serial Number: | 73593337 | AXID |
| Serial Number: | 78172324 | INNOPRAN XL |

CH $165.00 75888000

CORRESPONDENCE DATA

Fax Number: (704)625-9190
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*
Phone: 919 483 9618
Email: trademarks@gsk.com
Correspondent Name: Diane K. Fry
Address Line 1: Five Moore Drive
Address Line 2: C.3160.3D

| | |
|---|---|
| Address Line 4: | Research Triangle Pk, NORTH CAROLINA 27709 |
| ATTORNEY DOCKET NUMBER: | APP / DYNACIRC / USA |
| NAME OF SUBMITTER: | Diane K. Fry |
| Signature: | /dkf/ |
| Date: | 09/22/2010 |

Total Attachments: 4
source=credit suisse ag release#page1.tif
source=credit suisse ag release#page2.tif
source=credit suisse ag release#page3.tif
source=credit suisse ag release#page4.tif

# RELEASE OF SECURITY INTEREST IN TRADEMARKS

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS, dated as of the 22nd of September, 2010 (this "**Release**"), is executed by Credit Suisse AG (f/k/a Credit Suisse First Boston), a Swiss bank having a business address of 11 Madison Avenue, New York, New York 10010, as collateral agent ("**Collateral Agent**"), in favor of Reliant Pharmaceuticals, LLC, a Delaware limited liability company (the "**Company**") and any of its successors-in-interest. Capitalized terms used herein, but not otherwise defined, shall have the meaning ascribed to them in the Credit Agreement, dated as of September 3, 2004 (as amended, the "**Credit Agreement**"), among the Company and the lenders identified therein (the "**Lenders**").

WHEREAS, pursuant to that certain Pledge and Security Agreement dated as of September 3, 2004, the Collateral Agent has been appointed as the collateral agent for the Lenders;

WHEREAS, Collateral Agent and the Company are parties to a certain Trademark Security Agreement, dated as of September 3, 2004 (the "**Trademark Security Agreement**");

WHEREAS, the Trademark Security Agreement granted the Collateral Agent, for the ratable benefit of the Lenders, a first priority security interest in, among other things, the Trademark Collateral (as defined in the Trademark Security Agreement), which included, without limitation, the trademarks listed on Schedule A attached hereto as security for certain obligations of the Company to the Collateral Agent (the "**Obligations**");

WHEREAS, the Collateral Agent recorded the Trademark Security Interest on September 8, 2004 at Reel 2935, Frame 0288 in the United States Patent and Trademark Office;

WHEREAS, the Collateral Agent recorded the Trademark Security Agreement on September 27, 2004 at Reel 3054, Frame 0524 in the United States Patent and Trademark Office; and

WHEREAS, pursuant to the Trademark Security Agreement, the Company or its successors-in-interest has satisfied all of the Obligations and Collateral Agent has agreed to release its security interests in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees as follows:

1. Termination and Release of Liens. The Collateral Agent hereby fully releases and terminates its security interests in and liens in all of the Company's right, title and interest in, to and under the Trademark Collateral, including, without limitation:

    a. all of the Company's now existing or hereafter acquired right, title and interest in and to: all trademarks which are now filed with the U.S. Patent and Trademark

Office, any similar office or agency of any state, territory or possession of the United States or Canada or any similar office or agency of any other country or used in the United States, any state, territory or possession thereof including, without limitation, Puerto Rico, or any other country and (i) any renewals thereof, (ii) all income, royalties, damages and payments now and hereafter due or payable with respect thereto, including, without limitation, payments under all licenses entered into in connection therewith and damages and payments for past or future infringements thereof, (iii) the right to sue for past, present and future infringements thereof, (iv) all documents, packages, prints and labels on which said Trademark collateral has appeared and all designs and general intangibles of the like nature, and (v) all rights corresponding thereto throughout the world

b. the goodwill of the Company's business connected with or symbolized by the Trademark Collateral; and

c. any and all of the proceeds of any of the foregoing, including, without limitation, any claims by the Company against third parties for infringement of the Trademark Collateral or of any license with respect thereto.

2. Further Assurances. The Collateral Agent further agrees, at the sole cost and expense of the Company, to perform all acts reasonably necessary to effect the release and termination of its security interest and liens, including, but not limited to the recording, filing and entering into any agreements, documents, forms or papers needed to accomplish such release and termination.

3. Governing Law. This Release shall be governed by and construed in accordance with the laws of the State of New York, without regard to the principles of conflicts of laws of such state (other than Sections 5-1401 and 5-1402 of the General Obligations Law of the State of New York).

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be duly executed and delivered as of the day and year first above written.

**CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH** (f/k/a Credit Suisse First Boston), as the Collateral Agent

By: _____
Name: James Moran
Title: Managing Director

By: _____
Name: Vipul Kumar
Title: VICE PRESIDENT

## SCHEDULE A

| Registered US Trademark Serial No. | Name of Trademark |
|---|---|
| 75888000 | Reliant Pharmaceuticals |
| 75516493 | [capsule design] |
| 74162689 | DynaCirc CR |
| 73591689 | DynaCirc |
| 73593337 | Axid |
| 78172324 | InnoPran XL |